Reports Q1 revenue $2.7B, consensus $2.62B. “Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter (BAX) continues to take the decisive steps necessary to fulfill our commitment to delivering better and more consistent results for our shareholders. I want to thank our colleagues for their resilience, dedication and mission-driven focus to support the more than 350 million patients around the world who rely on us annually.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Is BAX a Buy, Before Earnings?
- Baxter: Turnaround Progress but Muted 2026 Outlook Keeps Hold Rating and $22 Price Target Unchanged
- Baxter showcases Global Surgical Solutions portfolio at AORN Conference
- Baxter price target lowered to $22 from $23 at Evercore ISI
- Baxter introduces IV Verify Line Labeling System
